{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-22-000033","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2022-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.940073+00:00","generated_at":"2026-06-23T05:57:17.328264+00:00","sec_items":["4.01","5.07","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Skye shareholders approve acquisition of Emerald Health; Phase 1 trial imminent","bullets":["97% of votes cast (excluding affiliates) approved the acquisition of Emerald Health Therapeutics.","Expected closing before October 15, subject to Canadian Securities Exchange listing approval.","Phase 1 trial of SBI-100 in glaucoma to start in Australia; first dosing expected in November 2022.","Final manufacturing step is quality testing; drug product expected to be available in October 2022.","Auditor changed from Friedman LLP to Marcum LLP following merger; no disagreements reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-22-000033","json":"https://secwatch.observer/filing/0001516551-22-000033.json","markdown":"https://secwatch.observer/filing/0001516551-22-000033.md","text":"https://secwatch.observer/filing/0001516551-22-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655122000033/0001516551-22-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655122000033/skye-20220929.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:57:17.328264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}